RCT: Oral Nirmatrelvir for high-risk adults with Covid-19 reduces the risk of hospitalization by 89%.
17 Feb, 2022 | 10:14h | UTCAudio Interview: A New Antiviral against Covid-19 – new England Journal of Medicine
Related:
Commentary on Twitter
The Paxlovid pill (Nirmatrelvir) randomized, placebo-controlled trial published @NEJM:
89% efficacy vs Covid hospitalizations or deaths, and quick reduction of viral load.
The active pills had less serious adverse events or discontinuations than placebohttps://t.co/HBMRZt4wBo pic.twitter.com/LDQv41O56c— Eric Topol (@EricTopol) February 16, 2022